{"result": {"id": "bc30a3c7-ae0c-49c1-b73d-e7dc1cc06e35", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "Here are additional entities and relationships that were missed in the initial extraction, formatted as requested:\n\n(\"entity\"<|>DIABETES CARE<|>ORGANIZATION<|>Diabetes Care is a journal publishing research on diabetes and related conditions\")\n##\n(\"entity\"<|>JAMA<|>ORGANIZATION<|>JAMA is a medical journal publishing research on various health topics including diabetes and hypertension\")\n##\n(\"entity\"<|>PLOS ONE<|>ORGANIZATION<|>PLOS One is a scientific journal publishing research across multiple disciplines including medicine\")\n##\n(\"entity\"<|>JOURNAL OF THE AMERICAN HEART ASSOCIATION<|>ORGANIZATION<|>Journal publishing cardiovascular research including studies on diabetes and hypertension\")\n##\n(\"entity\"<|>BMJ<|>ORGANIZATION<|>British Medical Journal publishing medical research including diabetes studies\")\n##\n(\"entity\"<|>NEW ENGLAND JOURNAL OF MEDICINE<|>ORGANIZATION<|>Prestigious medical journal publishing research including diabetes and cardiovascular outcomes\")\n##\n(\"entity\"<|>METABOLITES<|>ORGANIZATION<|>Journal publishing research on metabolic processes including diabetes studies\")\n##\n(\"entity\"<|>JOURNAL OF HYPERTENSION<|>ORGANIZATION<|>Journal specializing in hypertension research\")\n##\n(\"entity\"<|>AMERICAN JOURNAL OF HYPERTENSION<|>ORGANIZATION<|>Journal publishing research on hypertension\")\n##\n(\"entity\"<|>LANCET<|>ORGANIZATION<|>Prestigious medical journal publishing research on various health topics\")\n##\n(\"entity\"<|>OBESITY REVIEWS<|>ORGANIZATION<|>Journal publishing research on obesity and related conditions\")\n##\n(\"relationship\"<|>DEBOERIH<|>DIABETES CARE<|>deBoerIH published research in Diabetes Care journal<|>5\")\n##\n(\"relationship\"<|>EMDIN CA<|>JAMA<|>Emdin CA published research in JAMA journal<|>5\")\n##\n(\"relationship\"<|>WANG J<|>PLOS ONE<|>Wang J published research in PLOS One journal<|>5\")\n##\n(\"relationship\"<|>BEDDHU S<|>JOURNAL OF THE AMERICAN HEART ASSOCIATION<|>Beddhu S published research in Journal of the American Heart Association<|>5\")\n##\n(\"relationship\"<|>BANGALORE S<|>BMJ<|>Bangalore S published research in BMJ journal<|>5\")\n##\n(\"relationship\"<|>WIVIOTT SD<|>NEW ENGLAND JOURNAL OF MEDICINE<|>Wiviott SD published research in New England Journal of Medicine<|>5\")\n##\n(\"relationship\"<|>ZINMAN B<|>NEW ENGLAND JOURNAL OF MEDICINE<|>Zinman B published research in New England Journal of Medicine<|>5\")\n##\n(\"relationship\"<|>PERKOVIC V<|>NEW ENGLAND JOURNAL OF MEDICINE<|>Perkovic V published research in New England Journal of Medicine<|>5\")\n##\n(\"relationship\"<|>CARUSO I<|>METABOLITES<|>Caruso I published research in Metabolites journal<|>5\")\n##\n(\"relationship\"<|>JORDAN J<|>JOURNAL OF HYPERTENSION<|>Jordan J published research in Journal of Hypertension<|>5\")\n##\n(\"relationship\"<|>BRAMLAGE P<|>AMERICAN JOURNAL OF HYPERTENSION<|>Bramlage P published research in American Journal of Hypertension<|>5\")\n##\n(\"relationship\"<|>WEBER MA<|>LANCET<|>Weber MA published research in Lancet journal<|>5\")\n##\n(\"relationship\"<|>ZOMER E<|>OBESITY REVIEWS<|>Zomer E published research in Obesity Reviews journal<|>5\")\n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1751559155, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 872, "prompt_tokens": 5952, "total_tokens": 6824, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 4352}, "prompt_cache_hit_tokens": 4352, "prompt_cache_miss_tokens": 1600}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: Clin Hypertens(Greenwich) ,  2019,21(11) :1654-1663.\n[600]  deBoerIH, BangaloreS, BenetosA, etal. Diabetesandhyper- tension: aposition statementbytheAmericanDiabetesAssocia- tion[J]. DiabetesCare,2017,40(9) :1273-1284.\n[601]  EmdinCA, RahimiK, NealB, etal. Bloodpressureloweringin type 2 diabetes:  a systematic review  and meta-analysis[J].   JAMA,2015,313(6) :603-615.\n[602]  WangJ, Chen Y, XuW , etal. Effectsofintensiveblood pres- sure lowering on mortality and cardiovascular and renal out- comes in type 2 diabetic patients:  a meta-analysis[J].  PLoS One,2019,14(4) :e0215362.\n[603]  Beddhu S, Chertow GM, GreeneT, etal.  Effects ofintensive systolic blood pressure lowering on cardiovascular events and mortalityin patients with type2 diabetes mellitus on standard glycemiccontrolandin thosewithoutdiabetesmellitus: reconci- ling resultsfrom ACCORDBP andSPRINT[J]. JAm HeartAs- soc,2018,7(18) :e009326.\n[604]  ManciaG, GrassiG.  Blood pressuretargetsin type2 diabetes.   Evidenceagainstorin favourofan aggressiveapproach[J]. Dia- betologia2018,61(3) :517-525.\n[605]  BangaloreS, FakheriR, TokluB, etal.  Diabetesmellitusas a compellingindication foruse ofrenin angiotensin system block- ers: systematic review and meta-analysis of randomized trials [J]. BMJ,2016,352:i438.\n[606]  MacDonaldTM, WilliamsB, WebbDJ, etal. Combinationtherapy issuperiorto sequentialmonotherapyfortheinitialtreatmentof hypertension: a double-blind randomized controlled trial[J]. J Am HeartAssoc,2017,6(11) :e006986.\n[607]  HuM, CaiX, YangW , etal. Effectofhemoglobin A1creduc- tion orweightreduction on blood pressurein glucagon-like pep- tide-1receptoragonistandsodium-glucosecotransporter-2inhib- itortreatmentin type2 diabetes mellitus: a meta-analysis[J]. J Am HeartAssoc,2020,9(7) :e015323.\n[608]  WiviottSD, RazI, BonacaMP, etal. Dapagliflozin and cardio-\n\n\n\nvascularoutcomes in type2 diabetes[J]. N EnglJ Med, 2019, 380(4) :347-357.\n[609]  Zinman B, WannerC, LachinJM, etal. Empagliflozin, cardio- vascularoutcomes, andmortalityintype2diabetes[J]. NEnglJ Med,2015,373(22) :2117-2128.\n[610]  PerkovicV, JardineMJ, NealB, etal.  Canagliflozin and renal outcomesin type2 diabetesandnephropathy[J]. NEnglJ Med,  2019,380(24) :2295-2306.\n[611]  Caruso I, CignarelliA, SoriceGP, etal. Cardiovascularandre- naleffectiveness ofGLP-1 receptor agonistsvs.  other glucose- loweringdrugsintype2diabetes: asystematicreview andmeta- analysisofreal-world studies[J]. Metabolites,2022,12(2) :183.\n[612] JordanJ, Yumuk V, Schlaich M, etal. Jointstatementofthe European Association fortheStudyofObesityandtheEuropean Society of Hypertension: obesity and difficult to treat arterial hypertension[J]. J Hypertens,2012,30(6) :1047-1055.\n[613]  BramlageP, Pittrow D, Wittchen HU, etal.  Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled[J]. Am J Hypertens, 2004, 17(10) : 904- 910.\n[614]  CushmanWC, Ford CE, CutlerJA, etal.  Success and predic- tors of blood pressure control in diverse North American set- tings: theantihypertensive and lipid-lowering treatmentto pre- vent heart attack trial ( ALLHAT) [J].  J Clin Hypertens (Greenwich) ,2002,4(6) :393-404.\n[615]  Zomer E,  Gurusamy K,  Leach R,  et al.  Interventions that causeweightlossandtheimpactoncardiovascularriskfactors: a systematic review and meta-analysis[J].  Obes Rev, 2016, 17\n(10) :1001-1011.\n[616]  WeberMA, JamersonK, BakrisGL, etal. Effectsofbodysize andhypertensiontreatmentsoncardiovasculareventrates: suba- nalysisof the ACCOMPLISH randomised controlled trial[J].   Lancet,2013,381(9866) :537-545.\n[617]  RubinoDM, Greenway FL, Khalid\n######################\nOutput:", "role": "user"}, {"role": "assistant", "content": "(\"entity\"<|>AMERICAN DIABETES ASSOCIATION<|>ORGANIZATION<|>The American Diabetes Association is a professional organization that provides position statements on diabetes and related conditions such as hypertension>  \n##  \n(\"entity\"<|>DEBOERIH<|>PERSON<|>deBoerIH is a researcher or author associated with studies on diabetes and hypertension>  \n##  \n(\"entity\"<|>BANGALORE S<|>PERSON<|>Bangalore S is a researcher or author associated with studies on diabetes and hypertension>  \n##  \n(\"entity\"<|>BENETOS A<|>PERSON<|>Benetos A is a researcher or author associated with studies on diabetes and hypertension>  \n##  \n(\"entity\"<|>EMDIN CA<|>PERSON<|>Emdin CA is a researcher or author associated with studies on blood pressure lowering in type 2 diabetes>  \n##  \n(\"entity\"<|>RAHIMI K<|>PERSON<|>Rahimi K is a researcher or author associated with studies on blood pressure lowering in type 2 diabetes>  \n##  \n(\"entity\"<|>NEAL B<|>PERSON<|>Neal B is a researcher or author associated with multiple studies on diabetes and hypertension>  \n##  \n(\"entity\"<|>WANG J<|>PERSON<|>Wang J is a researcher or author associated with studies on intensive blood pressure lowering in type 2 diabetes>  \n##  \n(\"entity\"<|>CHEN Y<|>PERSON<|>Chen Y is a researcher or author associated with studies on intensive blood pressure lowering in type 2 diabetes>  \n##  \n(\"entity\"<|>XU W<|>PERSON<|>Xu W is a researcher or author associated with studies on intensive blood pressure lowering in type 2 diabetes>  \n##  \n(\"entity\"<|>BEDDHU S<|>PERSON<|>Beddhu S is a researcher or author associated with studies on intensive systolic blood pressure lowering in type 2 diabetes>  \n##  \n(\"entity\"<|>CHERTOW GM<|>PERSON<|>Chertow GM is a researcher or author associated with studies on intensive systolic blood pressure lowering in type 2 diabetes>  \n##  \n(\"entity\"<|>GREENE T<|>PERSON<|>Greene T is a researcher or author associated with studies on intensive systolic blood pressure lowering in type 2 diabetes>  \n##  \n(\"entity\"<|>MANCIA G<|>PERSON<|>Mancia G is a researcher or author associated with studies on blood pressure targets in type 2 diabetes>  \n##  \n(\"entity\"<|>GRASSI G<|>PERSON<|>Grassi G is a researcher or author associated with studies on blood pressure targets in type 2 diabetes>  \n##  \n(\"entity\"<|>FAKHERI R<|>PERSON<|>Fakheri R is a researcher or author associated with studies on diabetes mellitus and renin angiotensin system blockers>  \n##  \n(\"entity\"<|>TOKLU B<|>PERSON<|>Toklu B is a researcher or author associated with studies on diabetes mellitus and renin angiotensin system blockers>  \n##  \n(\"entity\"<|>MACDONALD TM<|>PERSON<|>MacDonald TM is a researcher or author associated with studies on combination therapy for hypertension>  \n##  \n(\"entity\"<|>WILLIAMS B<|>PERSON<|>Williams B is a researcher or author associated with studies on combination therapy for hypertension>  \n##  \n(\"entity\"<|>WEBB DJ<|>PERSON<|>Webb DJ is a researcher or author associated with studies on combination therapy for hypertension>  \n##  \n(\"entity\"<|>HU M<|>PERSON<|>Hu M is a researcher or author associated with studies on hemoglobin A1c reduction and blood pressure in type 2 diabetes>  \n##  \n(\"entity\"<|>CAI X<|>PERSON<|>Cai X is a researcher or author associated with studies on hemoglobin A1c reduction and blood pressure in type 2 diabetes>  \n##  \n(\"entity\"<|>YANG W<|>PERSON<|>Yang W is a researcher or author associated with studies on hemoglobin A1c reduction and blood pressure in type 2 diabetes>  \n##  \n(\"entity\"<|>WIVIOTT SD<|>PERSON<|>Wiviott SD is a researcher or author associated with studies on dapagliflozin and cardiovascular outcomes in type 2 diabetes>  \n##  \n(\"entity\"<|>RAZ I<|>PERSON<|>Raz I is a researcher or author associated with studies on dapagliflozin and cardiovascular outcomes in type 2 diabetes>  \n##  \n(\"entity\"<|>BONACA MP<|>PERSON<|>Bonaca MP is a researcher or author associated with studies on dapagliflozin and cardiovascular outcomes in type 2 diabetes>  \n##  \n(\"entity\"<|>ZINMAN B<|>PERSON<|>Zinman B is a researcher or author associated with studies on empagliflozin and cardiovascular outcomes in type 2 diabetes>  \n##  \n(\"entity\"<|>WANNER C<|>PERSON<|>Wanner C is a researcher or author associated with studies on empagliflozin and cardiovascular outcomes in type 2 diabetes>  \n##  \n(\"entity\"<|>LACHIN JM<|>PERSON<|>Lachin JM is a researcher or author associated with studies on empagliflozin and cardiovascular outcomes in type 2 diabetes>  \n##  \n(\"entity\"<|>PERKOVIC V<|>PERSON<|>Perkovic V is a researcher or author associated with studies on canagliflozin and renal outcomes in type 2 diabetes>  \n##  \n(\"entity\"<|>JARDINE MJ<|>PERSON<|>Jardine MJ is a researcher or author associated with studies on canagliflozin and renal outcomes in type 2 diabetes>  \n##  \n(\"entity\"<|>CARUSO I<|>PERSON<|>Caruso I is a researcher or author associated with studies on cardiovascular and renal effectiveness of GLP-1 receptor agonists>  \n##  \n(\"entity\"<|>CIGNARELLI A<|>PERSON<|>Cignarelli A is a researcher or author associated with studies on cardiovascular and renal effectiveness of GLP-1 receptor agonists>  \n##  \n(\"entity\"<|>SORICE GP<|>PERSON<|>Sorice GP is a researcher or author associated with studies on cardiovascular and renal effectiveness of GLP-1 receptor agonists>  \n##  \n(\"entity\"<|>JORDAN J<|>PERSON<|>Jordan J is a researcher or author associated with studies on obesity and arterial hypertension>  \n##  \n(\"entity\"<|>YUMUK V<|>PERSON<|>Yumuk V is a researcher or author associated with studies on obesity and arterial hypertension>  \n##  \n(\"entity\"<|>SCHLAICH M<|>PERSON<|>Schlaich M is a researcher or author associated with studies on obesity and arterial hypertension>  \n##  \n(\"entity\"<|>BRAMLAGE P<|>PERSON<|>Bramlage P is a researcher or author associated with studies on hypertension in overweight and obese primary care patients>  \n##  \n(\"entity\"<|>PITTROW D<|>PERSON<|>Pittrow D is a researcher or author associated with studies on hypertension in overweight and obese primary care patients>  \n##  \n(\"entity\"<|>WITTCHEN HU<|>PERSON<|>Wittchen HU is a researcher or author associated with studies on hypertension in overweight and obese primary care patients>  \n##  \n(\"entity\"<|>CUSHMAN WC<|>PERSON<|>Cushman WC is a researcher or author associated with studies on blood pressure control in diverse North American settings>  \n##  \n(\"entity\"<|>FORD CE<|>PERSON<|>Ford CE is a researcher or author associated with studies on blood pressure control in diverse North American settings>  \n##  \n(\"entity\"<|>CUTLER JA<|>PERSON<|>Cutler JA is a researcher or author associated with studies on blood pressure control in diverse North American settings>  \n##  \n(\"entity\"<|>ZOMER E<|>PERSON<|>Zomer E is a researcher or author associated with studies on weight loss and cardiovascular risk factors>  \n##  \n(\"entity\"<|>GURUSAMY K<|>PERSON<|>Gurusamy K is a researcher or author associated with studies on weight loss and cardiovascular risk factors>  \n##  \n(\"entity\"<|>LEACH R<|>PERSON<|>Leach R is a researcher or author associated with studies on weight loss and cardiovascular risk factors>  \n##  \n(\"entity\"<|>WEBER MA<|>PERSON<|>Weber MA is a researcher or author associated with studies on body size and hypertension treatments>  \n##  \n(\"entity\"<|>JAMERSON K<|>PERSON<|>Jamerson K is a researcher or author associated with studies on body size and hypertension treatments>  \n##  \n(\"entity\"<|>BAKRIS GL<|>PERSON<|>Bakris GL is a researcher or author associated with studies on body size and hypertension treatments>  \n##  \n(\"entity\"<|>RUBINO DM<|>PERSON<|>Rubino DM is a researcher or author associated with studies on weight loss and cardiovascular risk factors>  \n##  \n(\"entity\"<|>GREENWAY FL<|>PERSON<|>Greenway FL is a researcher or author associated with studies on weight loss and cardiovascular risk factors>  \n##  \n(\"entity\"<|>KHALID<|>PERSON<|>Khalid is a researcher or author associated with studies on weight loss and cardiovascular risk factors>  \n##  \n(\"entity\"<|>EUROPEAN ASSOCIATION FOR THE STUDY OF OBESITY<|>ORGANIZATION<|>The European Association for the Study of Obesity is a professional organization that studies obesity and related conditions>  \n##  \n(\"entity\"<|>EUROPEAN SOCIETY OF HYPERTENSION<|>ORGANIZATION<|>The European Society of Hypertension is a professional organization that studies hypertension and related conditions>  \n##  \n(\"entity\"<|>ALLHAT<|>EVENT<|>The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) is a clinical trial on blood pressure control>  \n##  \n(\"relationship\"<|>DEBOERIH<|>AMERICAN DIABETES ASSOCIATION<|>deBoerIH is associated with a position statement by the American Diabetes Association<|>5>  \n##  \n(\"relationship\"<|>BANGALORE S<|>AMERICAN DIABETES ASSOCIATION<|>Bangalore S is associated with a position statement by the American Diabetes Association<|>5>  \n##  \n(\"relationship\"<|>BENETOS A<|>AMERICAN DIABETES ASSOCIATION<|>Benetos A is associated with a position statement by the American Diabetes Association<|>5>  \n##  \n(\"relationship\"<|>JORDAN J<|>EUROPEAN ASSOCIATION FOR THE STUDY OF OBESITY<|>Jordan J is associated with a joint statement by the European Association for the Study of Obesity<|>5>  \n##  \n(\"relationship\"<|>YUMUK V<|>EUROPEAN ASSOCIATION FOR THE STUDY OF OBESITY<|>Yumuk V is associated with a joint statement by the European Association for the Study of Obesity<|>5>  \n##  \n(\"relationship\"<|>SCHLAICH M<|>EUROPEAN ASSOCIATION FOR THE STUDY OF OBESITY<|>Schlaich M is associated with a joint statement by the European Association for the Study of Obesity<|>5>  \n##  \n(\"relationship\"<|>JORDAN J<|>EUROPEAN SOCIETY OF HYPERTENSION<|>Jordan J is associated with a joint statement by the European Society of Hypertension<|>5>  \n##  \n(\"relationship\"<|>YUMUK V<|>EUROPEAN SOCIETY OF HYPERTENSION<|>Yumuk V is associated with a joint statement by the European Society of Hypertension<|>5>  \n##  \n(\"relationship\"<|>SCHLAICH M<|>EUROPEAN SOCIETY OF HYPERTENSION<|>Schlaich M is associated with a joint statement by the European Society of Hypertension<|>5>  \n##  \n(\"relationship\"<|>CUSHMAN WC<|>ALLHAT<|>Cushman WC is associated with the ALLHAT clinical trial<|>5>  \n##  \n(\"relationship\"<|>FORD CE<|>ALLHAT<|>Ford CE is associated with the ALLHAT clinical trial<|>5>  \n##  \n(\"relationship\"<|>CUTLER JA<|>ALLHAT<|>Cutler JA is associated with the ALLHAT clinical trial<|>5>  \n<|COMPLETE|>"}, {"content": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": 4000, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_extract-continuation-0_8ee4453b98c4266a93884ca55b16585c47fa12eff6590a00f1076bf84d894289_v2"}